Courtesy of the SBHCI.
Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr access.
This pilot study enrolled 50 patients with severe mitral regurgitation who were symptomatic and at a high surgical risk, or in whom surgery was contraindicated.
Read also: “TCT 2017 | MAVERIC: Results 6 Months After Transcatheter Mitral Valve Replacement”.
The rate of implantation success was 98%; the rate of 30-day mortality was 14% and 1-year survival was 77%. In patients who survived 1 year, there was no device dysfunction, hemolysis, thrombosis, or residual mitral regurgitation. After a 1-year follow-up, 79% of all survivors presented a New York Heart Association (NYHA) functional class I-II.
Conclusion
Treatment with the Intrepid device was feasible and able to correct mitral regurgitation in patients at high or extreme surgical risk.
Courtesy of the SBHCI.
Original title: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation.
Presenter: Paul Sorajja.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.